Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma: A case report.
Jing Zhang, Chun-Qiao Chen, Hui Huang et al.
✦ AI-curated · Sources linked
Case in brief
A 49-year-old man with stage IV clear cell renal cell carcinoma and lung metastases underwent palliative nephrectomy and received several targeted and immunotherapeutic regimens, but developed progressive pulmonary disease, right adrenal and brain metastases, with cough, hemoptysis and persistent dizziness. After intracranial radiotherapy and further systemic treatment, he received camrelizumab with bevacizumab followed by bevacizumab maintenance, and later tislelizumab with bevacizumab. Disease remained stably controlled after sequential treatment, and overall survival was approximately 6 years at the latest follow-up; treatment was reported as well tolerated.
What made this case unusual
Sustained stable disease and approximately 6-year overall survival were reported in a heavily pretreated patient with metastatic disease, including brain metastasis, after sequential immune checkpoint inhibitor–bevacizumab regimens.
Diagnostic / clinical pearl
In this case, metastatic progression despite multiple prior regimens was followed by sustained disease stability with sequential immune checkpoint inhibitor–bevacizumab treatment; the report supports considering this approach as a possible salvage option, not as established comparative evidence.
Why it matters
The authors note that prospective studies and longer follow-up are needed to establish the clinical value of this combination strategy.